Divalproex in the treatment of posttraumatic stress disorder

A randomized, double-blind, placebo-controlled trial in a veteran population

Lori L. Davis, Jonathan R T Davidson, L. Charles Ward, Al Bartolucci, Charles L. Bowden, Frederick Petty

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster. METHOD: Under double-blind conditions, 85 US military veterans with PTSD were randomized to treatment with divalproex or placebo for 8 weeks. All patients who received at least 1 dose of medication and 1 postbaseline assessment (n = 82) were included in the efficacy population. The primary outcome measure was the hyperarousal subscale of the Clinician-Administered PTSD Scale. RESULT: There were no significant intergroup differences in primary or secondary end points. The final mean (SD) divalproex dose and serum valproic acid level were 2309 ± 507 mg/d and 82 ± 30 mg/L, respectively. CONCLUSIONS: Divalproex monotherapy was not effective in the treatment of chronic PTSD in predominantly older male combat veterans. Further study is needed to determine the efficacy of divalproex in the management of PTSD in women or civilians or in combination with antidepressants.

Original languageEnglish (US)
Pages (from-to)84-88
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume28
Issue number1
DOIs
StatePublished - Feb 2008

Fingerprint

Valproic Acid
Veterans
Post-Traumatic Stress Disorders
Placebos
Population
Therapeutics
Antidepressive Agents
Outcome Assessment (Health Care)
Serum

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Divalproex in the treatment of posttraumatic stress disorder : A randomized, double-blind, placebo-controlled trial in a veteran population. / Davis, Lori L.; Davidson, Jonathan R T; Ward, L. Charles; Bartolucci, Al; Bowden, Charles L.; Petty, Frederick.

In: Journal of Clinical Psychopharmacology, Vol. 28, No. 1, 02.2008, p. 84-88.

Research output: Contribution to journalArticle

Davis, Lori L. ; Davidson, Jonathan R T ; Ward, L. Charles ; Bartolucci, Al ; Bowden, Charles L. ; Petty, Frederick. / Divalproex in the treatment of posttraumatic stress disorder : A randomized, double-blind, placebo-controlled trial in a veteran population. In: Journal of Clinical Psychopharmacology. 2008 ; Vol. 28, No. 1. pp. 84-88.
@article{14a5b615d91a4adab3d05025abf857e1,
title = "Divalproex in the treatment of posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial in a veteran population",
abstract = "OBJECTIVE: To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster. METHOD: Under double-blind conditions, 85 US military veterans with PTSD were randomized to treatment with divalproex or placebo for 8 weeks. All patients who received at least 1 dose of medication and 1 postbaseline assessment (n = 82) were included in the efficacy population. The primary outcome measure was the hyperarousal subscale of the Clinician-Administered PTSD Scale. RESULT: There were no significant intergroup differences in primary or secondary end points. The final mean (SD) divalproex dose and serum valproic acid level were 2309 ± 507 mg/d and 82 ± 30 mg/L, respectively. CONCLUSIONS: Divalproex monotherapy was not effective in the treatment of chronic PTSD in predominantly older male combat veterans. Further study is needed to determine the efficacy of divalproex in the management of PTSD in women or civilians or in combination with antidepressants.",
author = "Davis, {Lori L.} and Davidson, {Jonathan R T} and Ward, {L. Charles} and Al Bartolucci and Bowden, {Charles L.} and Frederick Petty",
year = "2008",
month = "2",
doi = "10.1097/JCP.0b013e318160f83b",
language = "English (US)",
volume = "28",
pages = "84--88",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Divalproex in the treatment of posttraumatic stress disorder

T2 - A randomized, double-blind, placebo-controlled trial in a veteran population

AU - Davis, Lori L.

AU - Davidson, Jonathan R T

AU - Ward, L. Charles

AU - Bartolucci, Al

AU - Bowden, Charles L.

AU - Petty, Frederick

PY - 2008/2

Y1 - 2008/2

N2 - OBJECTIVE: To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster. METHOD: Under double-blind conditions, 85 US military veterans with PTSD were randomized to treatment with divalproex or placebo for 8 weeks. All patients who received at least 1 dose of medication and 1 postbaseline assessment (n = 82) were included in the efficacy population. The primary outcome measure was the hyperarousal subscale of the Clinician-Administered PTSD Scale. RESULT: There were no significant intergroup differences in primary or secondary end points. The final mean (SD) divalproex dose and serum valproic acid level were 2309 ± 507 mg/d and 82 ± 30 mg/L, respectively. CONCLUSIONS: Divalproex monotherapy was not effective in the treatment of chronic PTSD in predominantly older male combat veterans. Further study is needed to determine the efficacy of divalproex in the management of PTSD in women or civilians or in combination with antidepressants.

AB - OBJECTIVE: To evaluate the efficacy of divalproex for the treatment of posttraumatic stress disorder (PTSD) hyperarousal symptom cluster. METHOD: Under double-blind conditions, 85 US military veterans with PTSD were randomized to treatment with divalproex or placebo for 8 weeks. All patients who received at least 1 dose of medication and 1 postbaseline assessment (n = 82) were included in the efficacy population. The primary outcome measure was the hyperarousal subscale of the Clinician-Administered PTSD Scale. RESULT: There were no significant intergroup differences in primary or secondary end points. The final mean (SD) divalproex dose and serum valproic acid level were 2309 ± 507 mg/d and 82 ± 30 mg/L, respectively. CONCLUSIONS: Divalproex monotherapy was not effective in the treatment of chronic PTSD in predominantly older male combat veterans. Further study is needed to determine the efficacy of divalproex in the management of PTSD in women or civilians or in combination with antidepressants.

UR - http://www.scopus.com/inward/record.url?scp=38349128467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349128467&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e318160f83b

DO - 10.1097/JCP.0b013e318160f83b

M3 - Article

VL - 28

SP - 84

EP - 88

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -